StocksMedium•10 November 2026•
1 min read
Humacyte to File sBLA and Projects Doubling of Q4 Symvess Sales
Key Facts
1Humacyte plans to file a supplemental Biologics License Application (sBLA) for dialysis in November 2026.
2The company projects Q4 2026 Symvess sales to at least double those of Q3.
Humacyte plans to file a supplemental Biologics License Application (sBLA) for dialysis in November 2026. Seeking Alpha reported that the company projects Q4 2026 Symvess sales to at least double those recorded in the third quarter. This expansion follows a 151% surge in the company's Q3 sales performance.
HUMA closed at $0.4552 on November 9, 2026, after reaching a day high of $0.4934 and a low of $0.45. The updated guidance and regulatory timeline come as the company seeks to expand its commercial footprint in the biologics sector.